Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug ...

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 ...

The Indianapolis-based drugmaker reported profit of $7.4 billion for the first quarter, up from $2.8 billion in the same period a year earlier.

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on ...

Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for ...

If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound Eli Lilly's stock was downgraded over concerns about the scale and staying power of ...

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy now. On March 16, Eli Lilly and Company (NYSE:LLY) announced that its weight-loss drug Zepbound will be available for self-pay ...

Feb 18 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results in patients with the skin disease and ...

Mounjaro generated $8.66 billion in sales in the first quarter.

Eli Lilly and Novo Nordisk dominate the weight loss drug market with their injectable GLP-1 drugs. Both players recently won ...